Erlotinib price list for targeted drugs in 2025

Erlotinib (Erlotinib) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, widely used in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). As a targeted drug, erlotinib can precisely act on the signaling pathways of tumor cells, inhibit cancer cell proliferation and delay tumor progression. This targeting mechanism not only improves the efficacy, but also relatively reduces the systemic side effects caused by traditional chemotherapy, allowing patients to maintain their quality of life during treatment. Erlotinib, which is available in China, has been included in medical insurance. Patients can purchase it through formal channels. The price ranges from tens of yuan to six to seven hundred yuan. The specific reimbursement amount varies depending on regional and hospital policies. Patients are advised to consult the local hospital pharmacy for accurate information.

In overseas markets, erlotinib is available as both original and generic drugs. The price of original drugs is relatively high, while the price of generic drugs produced in India and other places is more economical, about 800 yuan, and the drug ingredients are basically the same as the original drugs. This provides an economically viable option for patients requiring long-term maintenance therapy. It should be noted that the price may change due to exchange rate fluctuations, market supply and demand, and import channels. Therefore, when purchasing, you should go through formal channels and choose the appropriate version under the guidance of a doctor. At the same time, patients need to follow the doctor's instructions and regularly review their liver function, kidney function and blood count while taking the medication to ensure the safety of the medication and the continued efficacy.

In general, erlotinib not only can accurately inhibit the growth of tumors related to EGFR mutations, but also provides a relatively economical and sustainable treatment option. Whether it is a version covered by domestic medical insurance or an overseas generic drug, it provides a guarantee for patients to obtain curative effect while reducing their economic burden. It is an important treatment option for patients with EGFR-mutated non-small cell lung cancer.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib